India, Uzbekistan Discuss Ways To Ensure Quality, Safety In Pharma Sector

New Delhi:  A delegation from Uzbekistan met officials from India’s Central Drugs Standard Control Organisation and discussed areas of collaboration, including the development of a pharmacovigilance system and reducing adverse effects of pharmaceutical products, officials said on Wednesday.

The delegation led by Alisher Temirov, Director of the Center for Pharmaceutical Products Safety, Uzbekistan had detailed discussions with Ranga Chandrashekar, Joint Drugs Controller of India’s regulatory body for drug control, regarding the quality and safety in the pharma sector, they added.

“Several important issues were discussed during the meeting, including the development of a pharmacovigilance system, reducing the adverse effects of pharmaceutical products, and identifying ways to prevent potential risks. It was emphasised that strengthening international cooperation in this area is crucial for ensuring public health,” an official statement said.

Temirov stressed the importance of developing effective mechanisms to prevent the entry of low-quality and counterfeit drugs into Uzbekistan’s pharmaceutical market.

“He emphasized the need for specific measures and close cooperation in verifying the authenticity of regulatory documents. The Indian officials expressed readiness to further improve internal control mechanisms and enhance cooperation with the Center to prevent the entry of pharmaceutical products that have not passed quality control into the Uzbek market,” the statement added.

The meeting was held during the 19th International Conference of Drug Regulatory Authorities (ICDRA).

Related Posts

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

New Delhi: The Centre has disclosed a significant enforcement action against hospitals found violating the guidelines of the Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), with 2,359 hospitals de-empanelled, 1,200…

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry